Thank you for your interest in Adaptimmune. We are a leader in the TCR T-cell therapy space focused on novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). The result of our efforts are SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapies that can recognize cancer proteins, and as a result detect and fight cancer within patients.
SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP and NY-ESO are moving into and through clinical studies. In addition to the targets for which clinical and preclinical evaluation is ongoing, we have identified over 30 intracellular target peptides preferentially expressed in cancer cells and are currently progressing 12 through unpartnered research programs.
|$5.70 0.24 (4.04%)Data provided by Nasdaq. Minimum 15 minutes delayed.|
|07/13/17||From the Desk of James Noble - Congratulations to Novartis on Winning FDA Panel Backing for its CAR T Therapy|
|On Tuesday July 12th, the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC) unanimously endorsed Novartis’s anti-CD19 CAR-T therapy (tisagenlecleucel, “CTL019”). This was a significant milestone in realizing the promise of engineered T-cell therapy, and it is likely that engineered T-cells targeting CD19 could be the first gene therapy approved for human use in the U.S.
This endorsement represents not only confidence in engineered T-cell therapy as an import... |
|06/05/17||Adaptimmune Announces an Oral Presentation on Data from NY-ESO Study in Synovial Sarcoma and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting|
|PHILADELPHIA and OXFORD, United Kingdom, June 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation on updated data from its NY-ESO study in synovial sarcoma, as well as four trials in progress posters. The data were presented at the 2017 ASCO annual meeting in Chicago, Illinois.
The Company will host a live teleconference and webcast slide presentation on June 6th from 8:00–9:00 AM EDT (1:00... |
|05/26/17||Adaptimmune Announces an Oral Presentation and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting|
|PHILADELPHIA and OXFORD, United Kingdom, May 26, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation, as well as four trials in progress posters, at the 2017 ASCO annual meeting in Chicago, Illinois on June 2 through June 6, 2017.
During an oral presentation scheduled for 1:15-1:27 PM CDT on June 5th, Dr. Sandra P. D’Angelo of the Memorial Sloan Kettering Cancer Center will present a full updat... |
|05/25/17||Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting NY-ESO in Combination with KEYTRUDA® (pembrolizumab) in Multiple Myeloma|
|PHILADELPHIA and OXFORD, United Kingdom, May 25, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated its study of NY-ESO SPEAR T‑cells targeting NY-ESO in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 inhibitor marketed by Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), in patients with multiple myeloma. This study is now open for enrollment.
|There are currently no events scheduled.|
Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just enter your e-mail address and click Submit.|